Compare Gilead Sciences, Inc. (GILD) vs AT&T Inc. (T) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs AT&T Inc. — how do they compare? Gilead Sciences, Inc. trades at $133.6 (market cap $163.51B), while AT&T Inc. trades at $21.58 (market cap $148.90B). The key difference: Gilead Sciences, Inc. and AT&T Inc. are close in size by market cap, and AT&T Inc. pays the higher dividend (5.18%). Which is the better fit depends on your goals.
| GILD | T | |
|---|---|---|
Market Cap | $163.51B | $148.90B |
Sector | Health | Media |
52-Week High | $155.80 | $29.62 |
52-Week Low | $108.22 | $20.49 |
Enterprise Value | $178.05B | $294.25B |
Dividend Yield | 2.49% | 5.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $130.04, down 1.04% on the day, with technical indicators showing a bearish bias while fundamentals remain strong. The company has beaten earnings expectations for three consecutive quarters, maintains robust profitability with a 30.99% net income margin, and recently secured FDA and European Commission approvals for expanded use of its oncology drug Trodelvy. Analyst consensus remains overwhelmingly positive with a $152.83 price target representing 17.5% upside potential.
The outlook for GILD is favorable with strong earnings momentum, expanding oncology portfolio, and solid cash generation, though risks include patent expirations, competitive pressures in HIV treatments, and recent negative cash flow trends. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharmaceutical company with growth catalysts, supported by Wall Street's bullish sentiment and recent regulatory wins.
AT&T (T) trades at $21.295, down 1.25% on the day, as technical indicators signal a bearish trend with resistance near $22. Fundamentally, the company shows strength with a low P/E of 7.22 and robust profitability, including a net income margin of 16.94% and consistent earnings beats in recent quarters. Recent news highlights innovation in 5G and drone detection, but investor sentiment is cautious due to competitive threats from SpaceX's Starlink.
The stock presents a value opportunity with a high dividend yield and attractive valuation, but faces significant risks from emerging satellite-based telecom competition. Analyst consensus is mixed, with a $26.18 price target suggesting upside potential, though near-term volatility may persist amid market concerns over industry disruption.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About AT&T Inc.
AT&T Inc. is a communications holding company. The Company, through its subsidiaries and affiliates, provides local and long-distance phone service, wireless and data communications, Internet access and messaging, IP-based and satellite television, security services, telecommunications equipment, and directory advertising and publishing.
Read more on T →
